PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
In recurrent prostate cancer, prostate-specific member antigen PET/CT changes management in two thirds of cases
New research confirms high impact in detection and management of disease.
From an article Newswire article shared through Us TOO
Analysis of particles shed by tumors points to new, less invasive ways to diagnose malignancies
African American men likely face a much higher risk in delaying early detection and treatment.
A non-invasive test less painful and cheaper than a tissue biopsy being used to tailor treatment
From Us TOO International's June HotSHEET, page 7
A Medscape Medical News article published in Us Too's June HotSheet
A Science Daily article from Society of Nuclear Medicine and Molecular Imaging
From a Newswire article shared by Us Too
Update from the ORIOLE Study